World Lifestyler
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
No Result
View All Result
WORLD LIFESTYLER
No Result
View All Result
Home Press Releases Press Releases - Lifestyle

Sedogen announces issuance of new U.S. patent for the use of diazoxide formulations to treat behavioral symptoms in Prader-Willi syndrome

Cision PR Newswire by Cision PR Newswire
April 15, 2026
in Press Releases - Lifestyle
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

CHICAGO, April 15, 2026 /PRNewswire/ — Sedogen LLC, a biopharmaceutical company dedicated to improving the lives of individuals and families affected by Prader-Willi syndrome, announced today the issuance of a new patent (12,589,098) from the U.S. Patent and Trademark Office related to the use of pharmaceutical formulations of diazoxide to reduce behavioral symptoms in Prader-Willi syndrome (PWS). These behavioral symptoms include food-related behavioral symptoms, such as preoccupation with food and constant thoughts about food.


Dedicated to the Prader-Willi syndrome community

“My daughter was the first individual living with PWS that was treated with diazoxide, dating back to 2013. I’m thrilled that this patent was issued after much effort, strengthening our commitment to serve the Prader-Willi syndrome community,” said Sara Cotter, Founder and President of Sedogen.

U.S. Patent Number 12,589,098 was issued on March 31, 2026 and expires June 6, 2034.

About PWS

Prader-Willi syndrome is a rare, complex, multisystem, neurodevelopmental disorder that occurs spontaneously in approximately 1 in 16,000 births.i The underlying cause of PWS is the lack of expression of paternally inherited imprinted genes on chromosome 15q11-q13. These genetic anomalies lead to a distinctive phenotype that includes mild to moderate levels of intellectual disability, developmental delays, growth hormone deficiency, hypogonadism, failure to thrive during infancy, and ultimately hyperphagia (the syndrome’s hallmark symptom). For more information about PWS, visit the Foundation for Prader-Willi Research (www.fpwr.org) and Prader-Willi Syndrome Association (www.pwsausa.org).

iBurd L, Vesely B, Martsolf J, Kerbeshian J. Prevalence study of Prader-Willi syndrome in North Dakota. Am J Med Genet. 1990; 37:97-9.

About Sedogen

Sedogen LLC is a parent-led company dedicated to improving the lives of individuals and families affected by Prader-Willi syndrome.

www.sedogen.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/sedogen-announces-issuance-of-new-us-patent-for-the-use-of-diazoxide-formulations-to-treat-behavioral-symptoms-in-prader-willi-syndrome-302743406.html

SOURCE Sedogen

Cision PR Newswire

Cision PR Newswire

Related Posts

The One Where SHEGLAM Meets FRIENDS

October 26, 2026

Rapidus and HCLTech announce partnership for next-generation semiconductor technologies

October 26, 2026

Parloa’s Agent Management Platform now sold as an SAP Solution Extension for agentic customer interactions

October 26, 2026

Temu Partners with Spain’s Recyclia to Support Seller Extended Producer Responsibility

October 26, 2026

SUNON Brings AI, Nature and Human-Centered Design to ORGATEC 2026

October 26, 2026

Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma

October 26, 2026

Popular News

  • Mendez & Sanchez Finds Three Counties Accounted for Nearly Two-Thirds of California Rideshare Trips

    0 shares
    Share 0 Tweet 0
  • Highmark Health Reports Revenue of $26.5 billion, $741 million in Operating Income, for Nine Months ended Sept. 30, 2026

    0 shares
    Share 0 Tweet 0
  • AZ Blue Health Choice Expands Access to Resources for Page Families

    0 shares
    Share 0 Tweet 0
  • Payoneer Receives OCC Conditional Approval to Form Stablecoin National Trust Bank

    0 shares
    Share 0 Tweet 0
  • S&P Global to Present at Goldman Sachs Financial Services Conference on December 8, 2026

    0 shares
    Share 0 Tweet 0

About & Contact

  • About Us
  • Branding Style Guide
  • Contact Us
  • Help Centre
  • Media Kit
  • Site Map

Explore Content

  • Events
  • Newsletter
  • Press Releases
  • Topics

Legal & Privacy

  • Advertiser & Partner Policy
  • Communications & Newsletter Policy
  • Contributor Agreement
  • Copyright Policy
  • Privacy Policy
  • Prohibited Content Policy
  • Terms of Service

Tiny Media Brands

  • Silicon Valleys Journal
  • The AI Journal
  • The City Banker
  • The Wall Street Banker
  • World Lifestyler

© 2025 World Lifestyler

No Result
View All Result
  • Home

© 2025 World Lifestyler